LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
News|Articles|February 23, 2026
ASCO GU 2026 Preview: Highlights of Key Trials in Bladder, Kidney, Prostate, and Rare Cancers
Author(s)Tony Berberabe, MPH
Fact checked by: Jonah Feldman
Highlights from the 2026 ASCO Genitourinary Cancer Symposium featuring key presentations in bladder, kidney, prostate, and rare cancers.
Advertisement
Advertisement
In a preview of the upcoming 2026 ASCO Genitourinary Cancers Symposium, Rahul Parikh, MD, PhD, professor of medicine, University of Kansas and KU Medical Center shared his perspective on several presentations he is anticipating across the major disease settings.
Related to this article
Updated survival findings, perioperative treatment strategies, and circulating tumor DNA analyses highlight evolving approaches to genitourinary cancers.
Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders remaining event-free.
Five ESMO 2026 abstracts report responses with 4 antibody-drug conjugates in ovarian cancer and a subcutaneous HER2-directed ADC plus PD-L1 inhibitor in cervical cancer.
Late-breaking ESMO 2026 data show PFS gains with 3 antibody-drug conjugates, a 6-year OS benefit with adjuvant ribociclib, and no OS gain with pembrolizumab.
ADCs improved on chemotherapy-based regimens in PD-L1–negative and EGFR-mutated NSCLC, while chemotherapy plus pembrolizumab and pumitamig plus docetaxel showed activity in PD-L1–high and post-chemoimmunotherapy disease.
The approval expands the combination’s use to patients with androgen pathway modulation–naive or –sensitive disease based on phase 3 TALAPRO-3 findings.
ESMO 2026 Presidential Symposium III: ADC and immunotherapy highlights from the the ARTEMIS-011, TroFuse-005, KEYNOTE-C93, and MOIO trials.
Advertisement
Advertisement